Key result
Alamandine attenuates airway resistance and eosinophil infiltration back to control levels in asthmatic rats.
Why the study?
Alamandine, a renin-angiotensin system peptide with anti-inflammatory properties, remains poorly explored in allergic respiratory disease.
Does alamandine improve airway hyperresponsiveness and inflammation in an ovalbumin-induced asthma model?
Does alamandine improve airway hyperresponsiveness and inflammation in an ovalbumin-induced asthma model?
Alamandine demonstrates bronchoprotective and anti-inflammatory effects in a rat model of asthma, highlighting the ALA-MrgD/Mas axis as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Alamandine may target the ALA-MrgD/Mas axis in asthma; hypothesis-generating in an animal model and should not yet change practice.
Background: Asthma is a chronic inflammatory airway disease characterized by variable airflow obstruction and tissue remodeling. Alamandine (ALA), a renin–angiotensin system (RAS) peptide with anti-inflammatory properties, remains poorly explored in allergic respiratory disease. Objectives: This study evaluated prophylactic (33 days) and therapeutic (21 days) subcutaneous ALA (50 µg/kg/day) administration in an ovalbumin (OVA)-induced rat asthma model. Methods: Twenty male Wistar rats were assigned to four groups: control (CO), OVA with prophylactic ALA (ALA-P; days 1–33), OVA with therapeutic ALA (ALA-T; days 12–33), and OVA-only control (OVA). Rats were sensitized (days 1–3) and challenged with aerosolized OVA (days 6–33). On day 34, ventilatory mechanics were assessed via FlexiVent, including methacholine challenge (12.5 mg/mL). Pulmonary inflammation was evaluated by eosinophil quantification; MrgD/Mas and AT1 receptor expression by immunohistochemistry and Western blot, respectively. Results: OVA animals exhibited elevated baseline airway resistance and bronchoconstriction, and eosinophil infiltration. ALA-T significantly attenuated the respiratory symptoms, restoring airway resistance and eosinophil infiltration to CO-group levels, whereas ALA-P exhibited only a partial reduction. MrgD and Mas expression were elevated in OVA, reflecting compensatory RAS activation, but normalized in both ALA-treated groups. No significant differences in AT1 expression were observed. Conclusions: ALA likely exerts bronchoprotective and anti-allergic effects in this model via MrgD/Mas modulation. The ALA–MrgD/Mas axis represents a potential therapeutic target for allergic airway diseases, particularly when conventional treatments are insufficient.
No takes yet. Share an insight, caveat, or question.
Rech et al. (2026) studied Ovalbumin-induced asthma (n=20). Alamandine vs. Ovalbumin-only control (OVA) was evaluated on Airway resistance (Rn) post-methacholine challenge (p=<0.001). Therapeutic administration of alamandine attenuated airway resistance and eosinophil infiltration to control levels in an ovalbumin-induced asthma rat model.
Synapse has enriched 10 related papers. Consider them for comparative context: